La transparencia es una propiedad asombrosa y misteriosa que puede encontrarse en diversos objetos en nuestro entorno, desde el cristal de una ventana hasta el agua de un lago cristalino. ¿Alguna vez te has preguntado qué elementos intervienen en la transparencia de un objeto? …
La ciencia desvela los secretos de la transparencia de los objetos Read More »
JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers
NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that Dr. Sandra Wilks is scheduled to present the findings from her study of UroShield® at the International Continence Society (ICS) 2023 Conference.
Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities.
Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
Atamyo Therapeutics announced that the U.S. Food & Drug Administration has cleared its Investigational New Drug application for ATA-100 to proceed in a Phase 1b/2b clinical trial.
Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the following industry and investor conferences in September:
Immunic to Participate in Industry and Investor Conferences in September 2023 Read More »
Brii Biosciences Limited announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha in patients with chronic hepatitis B compared with PEG-IFNα only treatment.
Celltrion Group announced that the company will be attending the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023.
CANbridge Pharmaceuticals Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced its participation in two upcoming investor conferences.
CANbridge to Participate in Two Investor Conferences in September 2023 Read More »
